Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

202 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
James ND, Clarke NW, Cook A, Ali A, Hoyle AP, Attard G, Brawley CD, Chowdhury S, Cross WR, Dearnaley DP, de Bono JS, Diaz-Montana C, Gilbert D, Gillessen S, Gilson C, Jones RJ, Langley RE, Malik ZI, Matheson DJ, Millman R, Parker CC, Pugh C, Rush H, Russell JM, Berthold DR, Buckner ML, Mason MD, Ritchie AWS, Birtle AJ, Brock SJ, Das P, Ford D, Gale J, Grant W, Gray EK, Hoskin P, Khan MM, Manetta C, McPhail NJ, O'Sullivan JM, Parikh O, Perna C, Pezaro CJ, Protheroe AS, Robinson AJ, Rudman SM, Sheehan DJ, Srihari NN, Syndikus I, Tanguay JS, Thomas CW, Vengalil S, Wagstaff J, Wylie JP, Parmar MKB, Sydes MR; STAMPEDE Trials Collaborative Group. James ND, et al. Among authors: parker cc. Int J Cancer. 2022 Aug 1;151(3):422-434. doi: 10.1002/ijc.34018. Epub 2022 May 16. Int J Cancer. 2022. PMID: 35411939 Free PMC article. Clinical Trial.
Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.
de Bono JS, Bellmunt J, Attard G, Droz JP, Miller K, Flechon A, Sternberg C, Parker C, Zugmaier G, Hersberger-Gimenez V, Cockey L, Mason M, Graham J. de Bono JS, et al. J Clin Oncol. 2007 Jan 20;25(3):257-62. doi: 10.1200/JCO.2006.07.0888. J Clin Oncol. 2007. PMID: 17235043 Clinical Trial.
A comparison of the use of bony anatomy and internal markers for offline verification and an evaluation of the potential benefit of online and offline verification protocols for prostate radiotherapy.
McNair HA, Hansen VN, Parker CC, Evans PM, Norman A, Miles E, Harris EJ, Del-Acroix L, Smith E, Keane R, Khoo VS, Thompson AC, Dearnaley DP. McNair HA, et al. Among authors: parker cc. Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):41-50. doi: 10.1016/j.ijrobp.2007.09.002. Epub 2007 Nov 8. Int J Radiat Oncol Biol Phys. 2008. PMID: 17996391 Free article.
Outcome of early detection and radiotherapy for occult spinal cord compression.
Venkitaraman R, Barbachano Y, Dearnaley DP, Parker CC, Khoo V, Huddart RA, Eeles R, Horwich A, Sohaib SA. Venkitaraman R, et al. Among authors: parker cc. Radiother Oncol. 2007 Dec;85(3):469-72. doi: 10.1016/j.radonc.2007.10.043. Epub 2007 Nov 26. Radiother Oncol. 2007. PMID: 18036691
Clinical implications of introducing a new PSA assay.
Venkitaraman R, Norman AR, Iqbal J, Dearnaley DP, Horwich A, Huddart RA, Parker CC. Venkitaraman R, et al. Among authors: parker cc. Int Urol Nephrol. 2008;40(3):657-61. doi: 10.1007/s11255-007-9330-7. Epub 2008 Feb 6. Int Urol Nephrol. 2008. PMID: 18253858
202 results